Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.66 +0.31 (+1.09%)
Official Closing Price Updated: 7:00 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,335,886
Open 28.78
Bid (Size) 28.77 (1)
Ask (Size) 28.79 (1)
Prev. Close 28.35
Today's Range 28.42 - 29.23
52wk Range 25.20 - 37.80
Shares Outstanding 5,606,688,356
Dividend Yield 5.72%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector. 
Via Benzinga
Why Pfizer Stock Is Moving Higher on Thursday
Pfizer announced it will advance development of its once-daily Danuglipron. 
Via Benzinga

Performance

YTD
-3.60%
-3.60%
1 Month
+2.25%
+2.25%
3 Month
+8.81%
+8.81%
6 Month
+0.92%
+0.92%
1 Year
-20.37%
-20.37%

More News

Read More
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
Wall Street Weighs In As Pfizer Targets $100 Billion Weight Loss Market
Via Talk Markets
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
Via Benzinga
Pfizer Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Pfizer Stock Jumps After Picking Daily Pill As Weight-Loss Drug
Via Investor's Business Daily
Premarket Stocks: 3 Fast Movers And 1 In A Buy Zone
Via Investor's Business Daily
7 High-Yield Dividend Stocks to Buy and Hold Forever: July Edition
Via InvestorPlace
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
Via InvestorPlace
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
From Pfizer Inc.
Via Business Wire
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
Via InvestorPlace
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
Via Benzinga
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
Via Talk Markets
Topics Stocks
Exposures US Equities
3 No-Brainer Stocks to Buy With $100 Right Now
Via The Motley Fool
Pfizer Launches Process To Identify Chief Scientific Officer Successor
Via Benzinga
The 3 Most Undervalued Large-Cap Stocks to Buy in July 2024
Via InvestorPlace
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
Via Investor Brand Network
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
From Pfizer Inc.
Via Business Wire
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
Via AB Newswire
Exposures COVID-19 Product Safety
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
Via Benzinga
3 Overlooked Giants-in-the-Making for Patient Investors
Via InvestorPlace
Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.